↓ Skip to main content

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

Overview of attention for article published in Breast Cancer Research, September 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
1 X user
patent
5 patents

Citations

dimensions_citation
119 Dimensions

Readers on

mendeley
218 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
Published in
Breast Cancer Research, September 2013
DOI 10.1186/bcr3480
Pubmed ID
Authors

Wenle Xia, Emanual F Petricoin, Sumin Zhao, Leihua Liu, Takuya Osada, Qing Cheng, Julia D Wulfkuhle, William R Gwin, Xiaoyi Yang, Rosa I Gallagher, Sarah Bacus, H Kim Lyerly, Neil L Spector

Abstract

The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted tumors. Although lapatinib, an FDA-approved small-molecule HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), represents a significant therapeutic advancement in the treatment of HER2+ breast cancers, responses to lapatinib have not been durable. Consequently, elucidation of mechanisms of acquired therapeutic resistance to HER-directed therapies is of critical importance.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 218 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 1%
United Kingdom 1 <1%
Unknown 214 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 61 28%
Student > Ph. D. Student 22 10%
Researcher 22 10%
Student > Master 9 4%
Student > Doctoral Student 5 2%
Other 10 5%
Unknown 89 41%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 41 19%
Biochemistry, Genetics and Molecular Biology 33 15%
Agricultural and Biological Sciences 28 13%
Medicine and Dentistry 15 7%
Chemistry 3 1%
Other 6 3%
Unknown 92 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2023.
All research outputs
#5,240,751
of 25,374,917 outputs
Outputs from Breast Cancer Research
#616
of 2,053 outputs
Outputs of similar age
#43,810
of 213,374 outputs
Outputs of similar age from Breast Cancer Research
#12
of 33 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.